{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:56:40Z","timestamp":1789448200033,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62681-2","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T17:33:05Z","timestamp":1754587985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-1328","authenticated-orcid":false,"given":"C\u00e9cile","family":"Herate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ferrier-Rembert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-8481","authenticated-orcid":false,"given":"Francis","family":"Relouzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Gallou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Letscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-0263","authenticated-orcid":false,"given":"Mariangela","family":"Cavarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-6313","authenticated-orcid":false,"given":"Nathalie","family":"Dereuddre-Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Delache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Timera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Jarjaval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-9277","authenticated-orcid":false,"given":"Laetitia","family":"Bossevot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ludot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1025-896X","authenticated-orcid":false,"given":"Maxence","family":"Lechemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4928-4484","authenticated-orcid":false,"given":"Roger","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"62681_CR1","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMra2208860","volume":"387","author":"A Gessain","year":"2022","unstructured":"Gessain, A., Nakoune, E. & Yazdanpanah, Y. Monkeypox. N. Engl. J. Med. 387, 1783\u20131793 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62681_CR2","unstructured":"World-Health-Organization. WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. https:\/\/www.who.int\/azerbaijan\/news\/item\/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern, (2022)."},{"key":"62681_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45110-8","volume":"15","author":"T Ward","year":"2024","unstructured":"Ward, T. et al. Understanding the infection severity and epidemiological characteristics of mpox in the UK. Nat. Commun. 15, 2199 (2024).","journal-title":"Nat. Commun."},{"key":"62681_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1473-3099(22)00411-X","volume":"22","author":"N Girometti","year":"2022","unstructured":"Girometti, N. et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect. Dis. 22, 1321\u20131328 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"62681_CR5","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1056\/NEJMoa2207323","volume":"387","author":"JP Thornhill","year":"2022","unstructured":"Thornhill, J. P., Antinori, A. & Orkin, C. M. Monkeypox virus infection across 16 countries - April-June 2022. Reply. N. Engl. J. Med. 387, e69 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62681_CR6","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1093\/cid\/ciaa143","volume":"71","author":"D Ogoina","year":"2020","unstructured":"Ogoina, D. et al. Clinical course and outcome of human monkeypox in Nigeria. Clin. Infect. Dis. 71, e210\u2013e214 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"62681_CR7","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1086\/498115","volume":"41","author":"GD Huhn","year":"2005","unstructured":"Huhn, G. D. et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis. 41, 1742\u20131751 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"62681_CR8","doi-asserted-by":"publisher","first-page":"101030","DOI":"10.1016\/j.onehlt.2025.101030","volume":"20","author":"A Bogacka","year":"2025","unstructured":"Bogacka, A. et al. Mpox unveiled: global epidemiology, treatment advances, and prevention strategies. One Health 20, 101030 (2025).","journal-title":"One Health"},{"key":"62681_CR9","doi-asserted-by":"publisher","first-page":"taad136","DOI":"10.1093\/jtm\/taad136","volume":"30","author":"S Musumeci","year":"2023","unstructured":"Musumeci, S., Laflamme, J., Kaiser, L., Segeral, O. & Calmy, A. Characteristics of possible mpox reinfection cases: literature review. J. Travel Med. 30, taad136 (2023).","journal-title":"J. Travel Med."},{"key":"62681_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(23)00492-9","volume":"24","author":"A Hazra","year":"2024","unstructured":"Hazra, A. et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect. Dis. 24, 57\u201364 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"62681_CR11","doi-asserted-by":"publisher","first-page":"102781","DOI":"10.1016\/j.jiph.2025.102781","volume":"18","author":"ZL Ahmed","year":"2025","unstructured":"Ahmed, Z. L. & Islam, M. R. The emergence of a novel mpox virus strain (clade Ib) in Central Africa: a global public health concern. J. Infect. Public Health 18, 102781 (2025).","journal-title":"J. Infect. Public Health"},{"key":"62681_CR12","doi-asserted-by":"crossref","unstructured":"Vakaniaki, E. H., et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat. Med. 30, 2791\u20132795 2024).","DOI":"10.1038\/s41591-024-03130-3"},{"key":"62681_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/cid\/ciac960","volume":"76","author":"LT Allan-Blitz","year":"2023","unstructured":"Allan-Blitz, L. T. et al. A position statement on Mpox as a sexually transmitted disease. Clin. Infect. Dis. 76, 1508\u20131512 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"62681_CR14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/cid\/ciac962","volume":"76","author":"A Hazra","year":"2023","unstructured":"Hazra, A. & Cherabie, J. N. Is Mpox a sexually transmitted infection? Why narrowing the scope of this disease may be harmful. Clin. Infect. Dis. 76, 1504\u20131507 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"62681_CR15","doi-asserted-by":"publisher","first-page":"e1004163","DOI":"10.1371\/journal.pmed.1004163","volume":"20","author":"N Low","year":"2023","unstructured":"Low, N. et al. Mpox virus and transmission through sexual contact: defining the research agenda. PLoS Med. 20, e1004163 (2023).","journal-title":"PLoS Med."},{"key":"62681_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","volume":"401","author":"O Mitj\u00e0","year":"2023","unstructured":"Mitj\u00e0, O. et al. Mpox in people with advanced HIV infection: a global case series. Lancet 401, 939\u2013949 (2023).","journal-title":"Lancet"},{"key":"62681_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(22)00651-X","volume":"23","author":"KM Angelo","year":"2023","unstructured":"Angelo, K. M. et al. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study. Lancet Infect. Dis. 23, 196\u2013206 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"62681_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.15585\/mmwr.mm7132e3","volume":"71","author":"D Philpott","year":"2022","unstructured":"Philpott, D. et al. Epidemiologic and clinical characteristics of monkeypox cases\u2014United States, May 17-July 22, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 1018\u20131022 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"62681_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1097\/QAD.0000000000003991","volume":"38","author":"MST Silva","year":"2024","unstructured":"Silva, M. S. T. et al. Mpox, sexually transmitted infections and combination prevention: insights from a major cohort in Rio de Janeiro, Brazil. Aids 38, 1845\u20131849 (2024).","journal-title":"Aids"},{"key":"62681_CR20","unstructured":"World-Health-Organization. Vaccins et vaccination contre la variole simienne: orientations provisoires, 16 novembre 2022. https:\/\/www.who.int\/fr\/publications\/i\/item\/WHO-MPX-Immunization, (2022)."},{"key":"62681_CR21","unstructured":"Prevention, C.f.D.C.a. Mpox Vaccine Recommendations. https:\/\/www.cdc.gov\/poxvirus\/mpox\/vaccines\/vaccine-recommendations.html, (2024)."},{"key":"62681_CR22","unstructured":"European-Center-for-Disease-Prevention-and-Control. Public health considerations for mpox in EU\/EEA countries. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/public-health-considerations-mpox-eueea-countries, (2023)."},{"key":"62681_CR23","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","volume":"30","author":"C Verheust","year":"2012","unstructured":"Verheust, C., Goossens, M., Pauwels, K. & Breyer, D. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30, 2623\u20132632 (2012).","journal-title":"Vaccine"},{"key":"62681_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3390\/vaccines11091410","volume":"11","author":"L Nave","year":"2023","unstructured":"Nave, L. et al. Immunogenicity and safety of modified vaccinia Ankara (MVA) vaccine\u2014a systematic review and meta-analysis of randomized controlled trials. Vaccines 11, 1410 (2023).","journal-title":"Vaccines"},{"key":"62681_CR25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMc2215846","volume":"388","author":"SE Frey","year":"2023","unstructured":"Frey, S. E., Goll, J. B. & Beigel, J. H. Erythema and induration after Mpox (JYNNEOS) vaccination Revisited. N. Engl. J. Med. 388, 1432\u20131435 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62681_CR26","unstructured":"Hillus, D. et al. Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study. Lancet Infect. Dis. 25, 775-787 (2025)."},{"key":"62681_CR27","doi-asserted-by":"publisher","first-page":"2300608","DOI":"10.2807\/1560-7917.ES.2024.29.21.2300608","volume":"29","author":"MR Haverkate","year":"2024","unstructured":"Haverkate, M. R. et al. Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023. Eur. Surveill. 29, 2300608 (2024).","journal-title":"Eur. Surveill."},{"key":"62681_CR28","doi-asserted-by":"crossref","unstructured":"Yeganeh, N., et al. Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023. Vaccine 42, 125987 (2024).","DOI":"10.1016\/j.vaccine.2024.05.035"},{"key":"62681_CR29","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","volume":"388","author":"NP Deputy","year":"2023","unstructured":"Deputy, N. P. et al. Vaccine effectiveness of JYNNEOS against Mpox disease in the United States. N. Engl. J. Med.388, 2434\u20132443 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62681_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","volume":"72","author":"AF Dalton","year":"2023","unstructured":"Dalton, A. F. et al. Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study\u2014United States, August 19, 2022-March 31, 2023. MMWR Morb. Mortal. Wkly. Rep. 72, 553\u2013558 (2023).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"62681_CR31","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3201\/eid3010.240292","volume":"30","author":"H Charles","year":"2024","unstructured":"Charles, H. et al. Mpox epidemiology and vaccine effectiveness, England, 2023. Emerg. Infect. Dis. 30, 2145\u20132148 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"62681_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.15585\/mmwr.mm7220a4","volume":"72","author":"ES Rosenberg","year":"2023","unstructured":"Rosenberg, E. S. et al. Effectiveness of JYNNEOS vaccine against diagnosed Mpox infection\u2014New York, 2022. MMWR Morb. Mortal. Wkly. Rep. 72, 559\u2013563 (2023).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"62681_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.15585\/mmwr.mm7422a3","volume":"74","author":"AK Rao","year":"2025","unstructured":"Rao, A. K. et al. Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for persons aged \u226518 years at risk for Mpox during an Mpox outbreak: recommendations of the advisory committee on immunization practices\u2014United States, 2023. MMWR Morb. Mortal. Wkly. Rep. 74, 385\u2013392 (2025).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"62681_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48180-w","volume":"15","author":"MT Berry","year":"2024","unstructured":"Berry, M. T. et al. Predicting vaccine effectiveness for mpox. Nat. Commun. 15, 3856 (2024).","journal-title":"Nat. Commun."},{"key":"62681_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/cid\/ciad645","volume":"78","author":"M Font\u00e1n-Vela","year":"2024","unstructured":"Font\u00e1n-Vela, M. et al. Effectiveness of modified vaccinia Ankara-Bavaria nordic vaccination in a population at high risk of Mpox: a Spanish cohort study. Clin. Infect. Dis. 78, 476\u2013483 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"62681_CR36","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.eclinm.2023.102420","volume":"68","author":"V Mazzotta","year":"2024","unstructured":"Mazzotta, V. et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. EClinicalMedicine 68, 102420 (2024).","journal-title":"EClinicalMedicine"},{"key":"62681_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.15585\/mmwr.mm7320a3","volume":"73","author":"SAJ Guagliardo","year":"2024","unstructured":"Guagliardo, S. A. J. et al. Monkeypox virus infections after 2 preexposure doses of JYNNEOS vaccine\u2014United States, May 2022-May 2024. MMWR Morb. Mortal. Wkly Rep. 73, 460\u2013466 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"62681_CR38","doi-asserted-by":"crossref","unstructured":"Phipps, K., et al. Short-lived neutralizing antibody responses to monkeypox virus in smallpox vaccine-naive persons after JYNNEOS vaccination. Emerg. Infect. Dis. 31, 237-245 (2025).","DOI":"10.3201\/eid3102.241300"},{"key":"62681_CR39","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2024.20951","volume":"332","author":"AY Collier","year":"2024","unstructured":"Collier, A. Y. et al. Decline of Mpox antibody responses after modified vaccinia Ankara-Bavarian nordic vaccination. Jama 332, 1669\u20131672 (2024).","journal-title":"Jama"},{"key":"62681_CR40","doi-asserted-by":"crossref","unstructured":"Selverian, C. N., et al. MPXV infection stimulates a more robust and durable neutralizing antibody response compared to MVA-BN vaccination. J. Infect. Dis. 231, 1069-1073 (2024).","DOI":"10.1093\/infdis\/jiae515"},{"key":"62681_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/jimmun\/vkae031","volume":"214","author":"A Wiedemann","year":"2025","unstructured":"Wiedemann, A. et al. Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines. J. Immunol. 214, 211\u2013222 (2025).","journal-title":"J. Immunol."},{"key":"62681_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl4317","volume":"16","author":"C Jacob-Dolan","year":"2024","unstructured":"Jacob-Dolan, C. et al. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Sci. Transl. Med. 16, eadl4317 (2024).","journal-title":"Sci. Transl. Med."},{"key":"62681_CR43","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1016\/j.cell.2023.08.023","volume":"186","author":"M Aid","year":"2023","unstructured":"Aid, M. et al. Mpox infection protects against re-challenge in rhesus macaques. Cell 186, 4652\u20134661.e4613 (2023).","journal-title":"Cell"},{"key":"62681_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2332669","volume":"13","author":"Q Li","year":"2024","unstructured":"Li, Q. et al. Mpox virus Clade IIb infected Cynomolgus macaques via mimic natural infection routes closely resembled human Mpox infection. Emerg. Microbes Infect. 13, 2332669 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"62681_CR45","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41564-022-01269-8","volume":"7","author":"G Frenois-Veyrat","year":"2022","unstructured":"Frenois-Veyrat, G. et al. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations. Nat. Microbiol. 7, 1951\u20131955 (2022).","journal-title":"Nat. Microbiol."},{"key":"62681_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41587-x","volume":"14","author":"AD Otter","year":"2023","unstructured":"Otter, A. D. et al. Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals. Nat. Commun. 14, 5948 (2023).","journal-title":"Nat. Commun."},{"key":"62681_CR47","doi-asserted-by":"crossref","unstructured":"Shen-Gunther, J., Cai, H. & Wang, Y. Genomic and antigenic differences between monkeypox virus and vaccinia vaccines: insights and implications for vaccinology. Int. J. Mol. Sci. 26, 1428 (2025).","DOI":"10.3390\/ijms26041428"},{"key":"62681_CR48","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","volume":"381","author":"PR Pittman","year":"2019","unstructured":"Pittman, P. R. et al. Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox. N. Engl. J. Med. 381, 1897\u20131908 (2019).","journal-title":"N. Engl. J. Med."},{"key":"62681_CR49","doi-asserted-by":"publisher","first-page":"1533533","DOI":"10.3389\/fphar.2025.1533533","volume":"16","author":"LA Bravo-V\u00e1zquez","year":"2025","unstructured":"Bravo-V\u00e1zquez, L. A., Bernal-V\u00e1zquez, D., Duttaroy, A. K. & Paul, S. Current status of next-generation vaccines against mpox virus: a scoping review. Front. Pharm. 16, 1533533 (2025).","journal-title":"Front. Pharm."},{"key":"62681_CR50","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1099\/0022-1317-75-6-1479","volume":"75","author":"MP Ravanello","year":"1994","unstructured":"Ravanello, M. P. & Hruby, D. E. Characterization of the vaccinia virus L1R myristylprotein as a component of the intracellular virion envelope. J. Gen. Virol. 75, 1479\u20131483 (1994).","journal-title":"J. Gen. Virol."},{"key":"62681_CR51","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/JVI.01706-07","volume":"82","author":"DH Davies","year":"2008","unstructured":"Davies, D. H. et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J. Virol. 82, 652\u2013663 (2008).","journal-title":"J. Virol."},{"key":"62681_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.vaccine.2009.10.078","volume":"28","author":"Y He","year":"2010","unstructured":"He, Y. et al. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge. Vaccine 28, 699\u2013706 (2010).","journal-title":"Vaccine"},{"key":"62681_CR53","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.chom.2022.11.003","volume":"30","author":"A Grifoni","year":"2022","unstructured":"Grifoni, A. et al. Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host Microbe 30, 1662\u20131670.e1664 (2022).","journal-title":"Cell Host Microbe"},{"key":"62681_CR54","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1086\/427265","volume":"191","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith, Y. et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect. Dis. 191, 372\u2013381 (2005).","journal-title":"J. Infect. Dis."},{"key":"62681_CR55","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1016\/j.cell.2024.08.043","volume":"187","author":"EM Mucker","year":"2024","unstructured":"Mucker, E. M. et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell 187, 5540\u20135553.e5510 (2024).","journal-title":"Cell"},{"key":"62681_CR56","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(22)02187-0","volume":"400","author":"JP Thornhill","year":"2022","unstructured":"Thornhill, J. P. et al. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. Lancet 400, 1953\u20131965 (2022).","journal-title":"Lancet"},{"key":"62681_CR57","doi-asserted-by":"publisher","first-page":"2200421","DOI":"10.2807\/1560-7917.ES.2022.27.22.2200421","volume":"27","author":"A Antinori","year":"2022","unstructured":"Antinori, A. et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Eur. Surveill. 27, 2200421 (2022).","journal-title":"Eur. Surveill."},{"key":"62681_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2301662120","volume":"120","author":"A Alcam\u00ed","year":"2023","unstructured":"Alcam\u00ed, A. Pathogenesis of the circulating mpox virus and its adaptation to humans. Proc. Natl. Acad. Sci. USA 120, e2301662120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62681_CR59","unstructured":"World-Health-Organization. WHO Director-General declares mpox outbreak a public health emergency of international concern. https:\/\/www.who.int\/news\/item\/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern, (2024)."},{"key":"62681_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virol.2008.04.003","volume":"377","author":"JW Golden","year":"2008","unstructured":"Golden, J. W. & Hooper, J. W. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377, 19\u201329 (2008).","journal-title":"Virology"},{"key":"62681_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1473-3099(23)00185-8","volume":"23","author":"AR Raccagni","year":"2023","unstructured":"Raccagni, A. R. et al. Two individuals with potential monkeypox virus reinfection. Lancet Infect. Dis. 23, 522\u2013524 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"62681_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijid.2023.10.017","volume":"137","author":"J Mart\u00ednez-Sanz","year":"2023","unstructured":"Mart\u00ednez-Sanz, J. et al. Description of mpox reinfection by whole genome sequencing. Int J. Infect. Dis. 137, 111\u2013113 (2023).","journal-title":"Int J. Infect. Dis."},{"key":"62681_CR63","unstructured":"World-Health-Organization. Mpox (monkeypox). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/monkeypox, (2022)."},{"key":"62681_CR64","unstructured":"Centers-for-Disease-Control-and-Prevention. Mpox Vaccine Recommendations. https:\/\/www.cdc.gov\/poxvirus\/mpox\/vaccines\/vaccine-recommendations.html, (2024)."},{"key":"62681_CR65","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1128\/JCM.42.5.1940-1946.2004","volume":"42","author":"VA Olson","year":"2004","unstructured":"Olson, V. A. et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J. Clin. Microbiol. 42, 1940\u20131946 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"62681_CR66","doi-asserted-by":"publisher","first-page":"D20","DOI":"10.1093\/nar\/gkab1112","volume":"50","author":"EW Sayers","year":"2022","unstructured":"Sayers, E. W. et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 50, D20\u2013d26 (2022).","journal-title":"Nucleic Acids Res."},{"key":"62681_CR67","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.21105\/joss.03773","volume":"6","author":"I Aksamentov","year":"2021","unstructured":"Aksamentov, I., Roemer, C., Hodcroft, E. & Neher, R. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw. 6, 3773 (2021).","journal-title":"J. Open Source Softw."},{"key":"62681_CR68","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/bioinformatics\/btu153","volume":"30","author":"T Seemann","year":"2014","unstructured":"Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068\u20132069 (2014).","journal-title":"Bioinformatics"},{"key":"62681_CR69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"62681_CR70","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","volume":"25","author":"AM Waterhouse","year":"2009","unstructured":"Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. & Barton, G. J. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189\u20131191 (2009).","journal-title":"Bioinformatics"},{"key":"62681_CR71","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","volume":"37","author":"BQ Minh","year":"2020","unstructured":"Minh, B. Q. et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol. Biol. Evol. 37, 1530\u20131534 (2020).","journal-title":"Mol. Biol. Evol."},{"key":"62681_CR72","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nmeth.4285","volume":"14","author":"S Kalyaanamoorthy","year":"2017","unstructured":"Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat. Methods 14, 587\u2013589 (2017).","journal-title":"Nat. Methods"},{"key":"62681_CR73","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/molbev\/msw046","volume":"33","author":"J Huerta-Cepas","year":"2016","unstructured":"Huerta-Cepas, J., Serra, F. & Bork, P. ETE 3: reconstruction, analysis, and visualization of phylogenomic data. Mol. Biol. Evol. 33, 1635\u20131638 (2016).","journal-title":"Mol. Biol. Evol."},{"key":"62681_CR74","first-page":"406","volume":"11","author":"A Cosma","year":"2004","unstructured":"Cosma, A. et al. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin. Diagn. Lab. Immunol. 11, 406\u2013410 (2004).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"62681_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcv.2004.07.005","volume":"32","author":"I Leparc-Goffart","year":"2005","unstructured":"Leparc-Goffart, I. et al. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J. Clin. Virol. 32, 47\u201352 (2005).","journal-title":"J. Clin. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62681-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:31:21Z","timestamp":1757356281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62681-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62681"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62681-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nathalie Silvestre and Catherine Brua are Transgene employees and may hold shares and\/or stock options in the company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7306"}}